Dr. Kumar on the Future Directions With Pirtobrutinib in MCL

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, discusses future directions with pirtobrutinib (LOXO-305) in mantle cell lymphoma (MCL).

Pirtobrutinib is a BTK inhibitor that has shown activity in patients with MCL, including those who previously received standard BTK inhibitors, Kumar says. Moreover, pirtobrutinib appears to be well tolerated and could offer patients a convenient, once-daily dosing option, Kumar explains.

Additional studies evaluating pirtobrutinib are planned, such as a phase 3 study comparing pirtobrutinib with investigator’s choice of ibrutinib (Imbruvica), acalabrutinib (Calquence), or zanubrutinib (Brukinsa), Kumar continues. Further research is needed to inform whether pirtobrutinib can be combined with other agents, such as venetoclax (Venclexta) to enhance the efficacy observed with the BTK inhibitor alone, Kumar concludes.